| Business Summary | | ILEX
Oncology,
Inc.
is
building
an
oncology-focused
pharmaceutical
company
by
assembling
and
developing
a
portfolio
of
novel
treatments
both
for
advanced-stage
cancers
and
for
early
stage
cancers
and
pre-malignant
conditions.
The
Company
has
a
portfolio
of
eight
anticancer
product
candidates
in
clinical
development
and
several
preclinical
stage
product
candidates.
In
addition
to
its
clinical
development
programs,
ILEX
is
conducting
drug
discovery
research,
translational
research
and
preclinical
studies
in
the
fields
of
angiogenesis
inhibition
and
targeted
medicinal
phosphonate
chemistry,
laying
the
groundwork
for
bringing
other
new
proprietary
product
candidates
into
its
pipeline.
The
Company's
most
advanced
product
candidate
is
Campath.
On
May
7,
2001,
the
U.S.
FDA
cleared
Campath
humanized
monoclonal
antibody
for
marketing
as
a
treatment
for
patients
with
B-cell
chronic
lymphocytic
leukemia
(B-CLL)
who
have
been
treated
with
alkylating
agents
and
have
failed
fludarabine
therapy. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ILXO
is
an
oncology
drug
development
company
that
develops
cancer
treatment
products
by
identifying,
developing,
manufacturing
and
regulating
approval
process
of
oncology
drugs.
For
the
six
months
ended
6/30/01,
revenues
decreased
6%
to
$13.3
million.
Net
loss
totaled
$41.7
million,
up
from
$7.9
million.
Results
reflect
a
decrease
in
product
development
revenues.
Net
loss
also
reflects
a
$21.1
million
in-process
R
and
D
charge
related
to
the
acquisition
of
Symphar
S.A. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Gary Woods, 57 Chairman,
Director | -- | -- | Richard Love, 57 Pres,
CEO, Director | $403K | -- | Gregory Weaver, 45 CFO,
VP | 201K | $132K | Ze'ev Shaked, Ph.D., 55 Exec.
VP, COO | 213K | -- | Michael Dwyer, 55 Exec.
VP, CBO | 299K | 551K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|